We are international
Donate
• about myeloma TEXT SIZE   
Ask Dr Durie

ask_dr_durie_banner

 

Have a question? Submit it to AskDrDurie@myeloma.org!
 

facebook
googleplus
twitter
youtube


IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org! For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org.

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!


 

 

 

#Ask Dr. Durie
    next      view all

07.21.16   Even though the kappa level is normal, the lambda level—the other normal light-chain—why is it also low?

In this video, Dr. Durie discusses why slight reductions in lambda levels in MM patients are not necessarily cause for alarm.

BOTTOM LINE:

Because the kappa, the myeloma light chain, is still in the normal range, the disease is in remission.


06.16.16   What is the difference between high-risk smoldering myeloma and high-risk myeloma?

In this week’s video, Dr. Brian Durie explains the meaning of the term “risk,” as it relates to myeloma.

BOTTOM LINE: 

The use of the word “risk” in myeloma staging can be confusing.


06.09.16   What is the value of ASCT if my myeloma protein level is already zero?

In this video, Dr. Brian Durie discusses how to treat myeloma, even if the myeloma protein level is zero.

The BOTTOM LINE:

Additional treatment at low levels of myeloma does have benefit.


06.02.16   What are the game-changing drugs for myeloma right now?

In this video, Dr. Durie sheds light on two or three new agents that may be effective to optimally treat myeloma.

BOTTOM LINE:

Many new therapies could be game-changers, but it will take time to know which work best.                                                        


05.26.16   Is it reasonable to take Zometa for longer than two years?

In this week’s video, Dr. Durie discusses how to safely use the bisphosphonate Zometa to control myeloma bone disease.

BOTTOM LINE:

Discontinue Zometa after two years unless bone disease is a major concern.


05.19.16   What is the new Black Swan project that studies families with myeloma?

In this week’s video, Dr. Brian Durie unveils a new BSRI project which studies genetic factors (though there are few) that are linked to myeloma.

BOTTOM LINE: 

If we identify genetic factors in MM, we can refine treatments accordingly.


05.12.16   What is this new Black Swan project called iStopMM?

In this week’s video, Dr. Brian Durie describes how the iStopMM study aims to prevent myeloma in the entire adult population of adults who are age 40 or over in Iceland.

BOTTOM LINE: While a seemingly lofty goal, iStopMM may bridge the pathway to eliminating myeloma.


05.05.16   Is it worth the risk of developing a secondary cancer after ASCT?

In this week’s Ask Dr. Durie, Dr. Brian Durie discusses how to learn about your own risk factors for secondary cancers when undergoing MM treatment.

BOTTOM LINE:

Know your own risk factors and discuss the pros and cons with your doctor.


04.28.16   How long does it take to assess if a particular treatment is working?

In this week’s video, Dr. Brian Durie provides insight on how to assess response to various myeloma treatments.

BOTTOM LINE:

By checking M-protein levels after each cycle of treatment, we can assess the true benefits of each therapy.


04.21.16   How common are low platelet counts after autologous stem cell transplant?

In this week’s video, Dr. Brian Durie explains that patients should keep a close eye on their platelet counts after undergoing a stem cell transplant.

The BOTTOM LINE: 

If platelet counts drop too low, therapy adjustments should be considered.


    next      view all